Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...

CFO Vanessa Kanu reported Q4 adjusted EBITDA of $195 million, representing a 9% increase year-over-year. She attributed the 27% increase in adjusted diluted EPS to strong margins and a lower tax rate ...

American importers have been stockpiling the popular Italian bubbly Prosecco as a hedge against the possible impact of ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Acadian Asset Management Incorporated Earnings Conference Call and Webcast for the Fourth Quarter 2024.

This is the conclusion of a recent analysis by commercial real estate investment firm Berkadia, which predicts Orlando will ...

Corteva's genetically modified Enlist platform has had wins over Bayer in recent years in gaining approval for its GMO seeds to be imported into China, which should boost Enlist's market share.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

New-home construction has been pointed to as a bright spot in an otherwise difficult housing market, but the prospect of ...